Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History

BACKGROUND: ATS and GOLD guidelines recommend treating low-exacerbation risk COPD patients with dual (LAMA/LABA) agents and reserving triple therapy (TT; LAMA/LABA and inhaled corticosteroids [ICS]) for severe cases with higher-exacerbation risk. However, TT often is prescribed across the COPD spect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sethi, Sanjay, Clark, Brendan, Bengtson, Lindsay G S, Buysman, Erin K, Palli, Swetha, Sargent, Andrew, Shaikh, Asif, Ferguson, Gary T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122846/
https://www.ncbi.nlm.nih.gov/pubmed/37155497
http://dx.doi.org/10.2147/COPD.S386962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122846/
https://www.ncbi.nlm.nih.gov/pubmed/37155497
http://dx.doi.org/10.2147/COPD.S386962

Ejemplares similares